Enzyme replacement therapy with α-galactosidase A has been used to treat Fabry disease since 2001. This article reviews the published evidence for clinical efficacy of the two available enzyme ...

The research, published by Cell Press on October 22nd in the American Journal of Human Genetics, describes a new and highly promising candidate for enzyme replacement therapy (ERT) for Fabry disease.

The enzyme replacement therapy market has gained significant momentum over recent years, driven by rising awareness of rare diseases and growing access to modern healthcare services. Enzyme ...

More information: Hemanth R. Nelvagal et al, Cross-species efficacy of enzyme replacement therapy for CLN1 disease in mice and sheep, Journal of Clinical Investigation (2022). DOI: 10.1172/JCI163107 ...

The enzyme replacement therapy market showcased robust growth in recent years, with a valuation of $7,780.69 million in 2020. Projections indicate continued expansion, foreseeing an estimated surge to ...

RNA gene scissors (CRISPR-Cas13) are gaining significant attention as a next-generation gene therapy with fewer side effects.

The enzyme replacement therapy market is expected to grow from US$ 9,673. 39 million in 2021 to US$ 15,184. 70 million by 2028; it is estimated to grow at a CAGR of 6. 8% from 2022 to 2028. The ...

Enzyme-replacement therapy is a potential treatment for lysosomal storage disease. 9–11 The first successful use of this therapy was in patients with Gaucher's disease, who were treated with ...